secwatch.observer — SEC 8-K summary
======================================

Issuer:     Enveric Biosciences, Inc. (ENVB)
CIK:        0000890821
Form:       8-K
Filed at:   2024-11-14T23:59:59+00:00
Accession:  0001493152-24-045840
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Enveric Biosciences Q3 net loss narrows to $2.1M; advances EB-003
-----------------------------------------------------------------

- Net loss of $2.1M ($0.24/share) vs $2.8M ($1.30/share) a year ago; cash $3.1M.
- Lead candidate EB-003 shows oral bioavailability and brain exposure; IND filing expected H2 2025.
- Out-licensed radiation dermatitis product to Aries Science & Technology and EB-002 to MycoMedica.
- Expanded patent estate with five new US patents for EVM301 portfolio.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/890821/000149315224045840/0001493152-24-045840-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/890821/000149315224045840/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-045840

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer